Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,601 to 2,620 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Torsemide vs Furosemide: All-cause Mortality, as Measured by Follow-up Phone Call or NDI | 373 of 1,431 374 of 1,428 | -0.1 points -3.3 to 3.1 | 2,859 | NCT03296813 TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure |
| Torsemide vs Furosemide: All-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death) | 677 of 1,431 704 of 1,428 | -2.0 points -5.6 to 1.7 | 2,859 | NCT03296813 TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure |
| Torsemide vs Furosemide: deaths from any cause | 373 of 1,431 374 of 1,428 | -0.1 points -3.3 to 3.1 | 2,859 | NCT03296813 TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure |
| Tofacitinib 10 mg vs Tofacitinib 5 mg or 10 mg: Number of Participants With Laboratory Abnormalities | 2,203 of 2,271 565 of 578 | -0.7 points -2.0 to 0.9 | 2,849 | NCT01163253 A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis |
| Tofacitinib 10 mg vs Tofacitinib 5 mg or 10 mg: Number of Participants With Clinically Significant Change From Baseline in Physical Examination | 683 of 2,268 191 of 577 | -3.0 points -7.3 to 1.2 | 2,845 | NCT01163253 A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis |
| Varenicline - With Antipsychotics as a Concomitant Drug vs Varenicline - Without Antipsychotics as a Concomitant Drug: Risk Factors for the Proportion of Responders - Antipsychotics as a Concomitant Drug. | 85 of 140 2,111 of 2,702 | -17.4 points -25.8 to -9.5 | 2,842 | NCT00772941 Drug Use Investigation Of Varenicline (Regulatory Post Marketing Commitment Plan) |
| Betamethasone vs Placebo: deaths from any cause | 2 of 1,429 0 of 1,402 | 0.1 points -0.2 to 0.5 | 2,831 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Betamethasone vs Placebo: serious adverse events | 13 of 1,429 12 of 1,402 | 0.1 points -0.7 to 0.8 | 2,831 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Intensive Blood-Pressure Lowering vs Guideline-Recommended Blood-Pressure Lowering: serious adverse events | 324 of 1,399 329 of 1,430 | 0.2 points -3.0 to 3.3 | 2,829 | NCT00716079 The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial |
| Betamethasone vs Placebo: Number of Infants With Neonatal Sepsis | 9 of 1,427 11 of 1,400 | -0.2 points -0.8 to 0.5 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Betamethasone vs Placebo: Neonatal Feeding Difficulty | 211 of 1,427 223 of 1,400 | -1.1 points -3.8 to 1.5 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Betamethasone vs Placebo: Number of Neonates With Necrotizing Enterocolitic (NEC) | 0 of 1,427 1 of 1,400 | -0.1 points -0.4 to 0.2 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Betamethasone vs Placebo: Number of Neonates Needing Surfactant Administration | 26 of 1,427 43 of 1,400 | -1.2 points -2.4 to -0.1 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Betamethasone vs Placebo: Neonatal Morbidity Composite | 81 of 1,427 90 of 1,400 | -0.8 points -2.5 to 1.0 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Betamethasone vs Placebo: Birth Weight Less Than 10th Percentile | 255 of 1,427 220 of 1,400 | 2.2 points -0.6 to 4.9 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Betamethasone vs Placebo: Number of Infants With Neonatal Apnea | 33 of 1,427 37 of 1,400 | -0.3 points -1.5 to 0.8 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Betamethasone vs Placebo: Number of Neonates With Hypothermia | 132 of 1,427 112 of 1,400 | 1.3 points -0.8 to 3.3 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Betamethasone vs Placebo: Neonates With Pneumonia | 6 of 1,427 13 of 1,400 | -0.5 points -1.2 to 0.1 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Betamethasone vs Placebo: Number of Neonates With Intraventricular Hemorrhage | 2 of 1,427 0 of 1,400 | 0.1 points -0.2 to 0.5 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
| Betamethasone vs Placebo: Number of Neonates With Pulmonary Air Leak | 5 of 1,427 6 of 1,400 | -0.1 points -0.6 to 0.4 | 2,827 | NCT01222247 Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial |
Code
curl "https://conductscience.org/api/comparisons/v1?page=131"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=131
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT03296813-a084e1c1",
"title": "Torsemide vs Furosemide: All-cause Mortality, as Measured by Follow-up Phone Call or NDI",
"summary": "373 of 1431 against 374 of 1428; risk difference -0.1 points, 95% interval -3.3 to 3.1; NCT03296813, TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure",
"record": "/library/comparisons/NCT03296813-a084e1c1",
"nct_id": "NCT03296813",
"kind": "outcome",
"participants": 2859,
"risk_difference": {
"value": -0.0012478786063692127,
"lower": -0.033437946453449954,
"upper": 0.030942685797791643
},
"group_1": "373 of 1,431",
"group_2": "374 of 1,428",
"difference": "-0.1 points",
"interval": "-3.3 to 3.1",
"trial_title": "TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure"
},
{
"id": "NCT03296813-ac4dc5ca",
"title": "Torsemide vs Furosemide: All-cause Mortality or All-cause Hospitalization, as Measured by Follow-up Phone Call or NDI (for Death)",
"summary": "677 of 1431 against 704 of 1428; risk difference -2.0 points, 95% interval -5.6 to 1.7; NCT03296813, TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure",
"record": "/library/comparisons/NCT03296813-ac4dc5ca",
"nct_id": "NCT03296813",
"kind": "outcome",
"participants": 2859,
"risk_difference": {
"value": -0.01990146163287121,
"lower": -0.05644226996069097,
"upper": 0.016714488756369647
},
"group_1": "677 of 1,431",
"group_2": "704 of 1,428",
"difference": "-2.0 points",
"interval": "-5.6 to 1.7",
"trial_title": "TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=132",
"request_id": "1DC6_ZOlqoOuTNA8"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant